Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

Researchers, including those at the University of North Carolina, US, found that the oral form of Semaglutide can ...

Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.

A groundbreaking study from the University of British Columbia has revealed a potentially disturbing side effect for those ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...